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Abstract Peritonitis remains a frequent complication of
peritoneal dialysis in children and is the most common
reason for technique failure. The microbiology is charac-
terized by a predominance of Gram-positive organisms,
with fungi responsible for less than 5% of episodes. Data
collected by the International Pediatric Peritonitis Registry
have revealed a worldwide variation in the bacterial
etiology of peritonitis, as well as in the rate of culture-
negative peritonitis. Risk factors for infection include
young age, the absence of prophylactic antibiotics at
catheter placement, spiking of dialysis bags, and the
presence of a catheter exit-site or tunnel infection. Clinical
symptoms at presentation are somewhat organism specific
and can be objectively assessed with a Disease Severity
Score. Whereas recommendations for empiric antibiotic
therapy in children have been published by the International
Society of Peritoneal Dialysis, epidemiologic data and
antibiotic susceptibility data suggest that it may be desirable
to take the patient- and center-specific history of micro-
organisms and their sensitivity patterns into account when
prescribing initial therapy. The vast majority of patients are
treated successfully and continue peritoneal dialysis, with
the poorest outcome noted in patients with peritonitis
secondary to Gram-negative organisms or fungi and in
those with a relapsing infection.
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Introduction
Chronic peritoneal dialysis (CPD) remains the most
common dialysis modality utilized for the management of
children with end-stage renal disease (ESRD), and its usage
is expanding in many developing countries [1–3]. Despite
the decreasing incidence of CPD-related infectious compli-
cations in both children and adults over the past two
decades, peritonitis remains the most significant complica-
tion of CPD in the pediatric population [4, 5]. Peritonitis
contributes to significant morbidity and can lead to
irreversible technique failure. Records from the United
States Renal Data System (USRDS) reveal that infectious
complications are the most frequent cause for hospitaliza-
tion among children receiving CPD and that the cumulative
incidence of hospitalization over a 36-month period
increased from 19.3% in the period 1995–1998 to 34.3%
in the period 1999–2002 [6]. Furthermore, according to
the data from the North American Pediatric Renal Trials
and Collaborative Studies (NAPRTCS), peritonitis is the
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CPD [2]. These facts mandate an effective approach to the
prevention and treatment of CPD-related infections in
children who face a lifetime of ESRD care.
To optimize the efficacy of antibiotic therapy, minimize
patient morbidity, and hopefully preserve the function of
the peritoneal membrane of patients prescribed CPD, the
International Society of Peritoneal Dialysis (ISPD) pub-
lished its first set of peritonitis treatment guidelines in 1983,
and updated versions of these guidelines were published in
1989, 1993, 1996, 2000 and, most recently, in 2005 [7–10].
However, with recognition of the presence of risk factors
and clinical features unique to children, an international
committee published largely opinion-based pediatric-
specific guidelines in 2000 [11]. Information derived from
the larger adult experience that was also applicable to
children was incorporated into the recommendations.
Subsequently, in order to assess the efficacy and validity
of these guidelines and to enhance existing knowledge
regarding the global bacteriology and antibiotic suscepti-
bility associated with peritonitis in children, the Interna-
tional Pediatric Peritonitis Registry (IPPR) was established
and collected/published data from a consortium of 44
pediatric dialysis centers in Europe, Turkey, Asia, and
America [12–15]. While the initial pediatric-specific guide-
lines published in 2000 form the backbone of this review,
the new information from the IPPR is incorporated in
pertinent sections.
Incidence of peritonitis
Over the past several decades, there has been a steady
decline in the rate of peritonitis in both children and adults
that is largely due to improvements in connection tech-
nology and a decreased incidence of touch contamination
[16–19]. While the rate of infection in adults has fallen to
0.5 episodes per patient–year (one infection every
24 months) in many centers, and rates as low as 0.23–
0.29 episodes per patient–year have been reported [20, 21],
the frequency of peritonitis in children regularly exceeds
that in adults. In the most recent annual report of the
NAPRTCS, which includes data collected through January
2007, there were 3892 episodes of peritonitis in 5764 years
of follow-up for an annualized rate of 0.68 (one episode
every 17.8 months) [2]. This rate has significantly
improved in comparison to the annualized rate of 0.91 that
was reported in the 1997 NAPRTCS data [22]. Similar to
previous reports, the current NAPRTCS report reveals an
inverse relationship between the age of the patient and
peritonitis rate, with the youngest patients (<1 year) having
an annualized rate of 0.86 (one infection every 13.9 months),
while the adolescents (>12 years) have a rate of 0.61 (one
infection every 19.8 months). These rates were derived from
clinical experience in the USA and are comparable to what
has been documented in European centers, but poorer than
theexceptionallylowrates(oneinfectionevery28.6months)
found among Japanese children [23–25].
Population-based peritonitis rates, however, can be
misleading because of an uneven distribution of individual
peritonitis rates. For example, only 38.8 and 52.4% of
patients in the NAPRTCS database had at least one episode
of peritonitis within 12 and 24 months of dialysis initiation,
respectively, and in those patients who experienced an
infection, the frequency varied from only one infection in
788 patients to more than eight infections in each of 48
patients [2]. This type of data emphasizes the potential
value of the determination of subject-specific peritonitis
incidence data [26].
The frequency of peritonitis is also affected by the type
of PD modality, with somewhat better rates for patients
who receive automated peritoneal dialysis (APD) versus
those that receive continuous ambulatory peritoneal dialysis
(CAPD). In the latest NAPRTCS annual data report, the
median time to the first peritonitis episode was shorter in
CAPD than APD patients; at 1 year post-dialysis initiation,
45.5% of CAPD patients experienced peritonitis compared
to 40.6% of APD patients [2]. Finally, patients on nocturnal
intermittent PD (cycler at night with a dry day) may have a
decreased risk of infection compared to those with a wet
day because the empty abdomen can enhance local immune
function [27].
Microbiology of peritonitis
Similar to adults, the majority of peritonitis episodes in
children on CPD are caused by bacteria, with fungi being
responsible for <5% of the episodes [28]. Historically, 50–
60% of the peritonitis episodes have been caused by Gram-
positive bacteria and 20–30% by Gram-negative organisms,
with cultures remaining negative in a substantial percentage
(<20%) of peritonitis episodes. Due to a steady decline in
the peritonitis rate over the last few decades, likely as a
result of improvements in connection technology and exit-
site care and in the prophylaxis for Staphylococcus aureus
nasal carriage, the distributive pattern of microorganisms
has changed and is currently reflected by a selective
decrease in the incidence of Gram-positive peritonitis,
leaving Gram-negative peritonitis as an increasingly impor-
tant infectious complication [21, 29, 30]. This pattern, apart
from minor disparities, had been believed to be fairly
consistent across different dialysis centers caring for
children and adults until a recent analysis of IPPR data
revealed a significant worldwide variation in dialysis-
associated peritonitis characteristics in children [13].
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gathered data on 501 episodes of peritonitis that occurred in
392 children. Only ten (2%) of these episodes were caused
by fungi. Of the remaining 491 episodes, 44% were caused
by Gram-positive organisms and 25% by Gram-negative
organisms; the culture remained negative in 31% of
episodes. While the results confirmed the earlier impression
of a decrease in the rate of Gram-positive infections, the
bacteriological profile of the Gram-positive organisms was
somewhat different from that recently reported in a survey
of >4000 episodes of peritonitis in adult patients from the
USA and Canada [31]. In contrast to the results of the adult
survey in which coagulase-negative staphylococci were
threefold more common than S. aureus as a cause of
peritonitis, staphylococcal organisms were nearly evenly
divided among the above two groups in the data gathered
by the IPPR (Fig. 1). Furthermore, there was significant
variation in the distribution of organisms between different
global regions (Fig. 2). Gram-positive infections were
predominant in Europe, with coagulase-negative staphylo-
cocci being most common in Eastern Europe, S. aureus
predominating in Western Europe, and Enterococcus species
being most prevalent in Turkey [13].
Worldwide variation was found among Gram-negative
organisms. Whereas Gram-negative organisms accounted
for 70% of culture-positive infections in Argentina, they
accounted for 46% of infections in the USA and for only 25%
of infections in European countries. While Pseudomonas was
the predominant Gram-negative organism in the USA, other
Gram-negative organisms were more common in Argentina
[13]. The reason for this marked geographical variation in
the bacterial spectrum is most likely multifactorial and may
include environmental influences (climate and humidity)
and various aspects of PD practices, such as exit-site care
and the routine use of topical antibiotic prophylaxis (vide
infra) [3].
Not only did the bacteriological profile differ from
region to region in the IPPR data, but there was also a
striking regional variation in the rate of culture-negative
peritonitis episodes. In Turkey and Mexico, effluent
cultures remained sterile in 42% and 67% of cases,
respectively in contrast to a sterile culture rate of 11–23%
in the other regions surveyed [13]. A survey of the
laboratory procedures practiced in the individual centers
did not reveal any systematic differences in culture
technique that would explain these marked differences,
but this aspect is currently being evaluated further. It is
possible that other issues, such as incubation of insufficient
effluent volumes, long transport times in rural areas, and
extreme ambient temperatures, may have adversely affected
the ability to obtain positive culture results. At the turn of
the century, a number of culture-negative peritonitis
episodes were reported that were associated with the usage
of icodextrin solution for PD [32–34]. Subsequent inves-
tigations revealed that these cases of sterile peritonitis were
caused by a peptidoglycan (released from Alicyclobacillus
acidocaldarius, a Gram-positive organism) contaminating
the cornstarch used for icodextrin production [35]. The
problem has since been resolved following implementation
of a routine serial monitoring program of icodextrin
solutions for peptidoglycan during the manufacturing
process. A recently concluded multicenter, longitudinal,
prospective cohort study that included 722 PD patients did
not find any difference in the rates of either infectious or
culture-negative peritonitis associated with the usage of
icodextrin [36].
As already mentioned, fungi account for only a minority
of peritonitis episodes and represent just 2% of episodes in
Fig. 1 Distribution of causative
organisms among 501 episodes
of peritonitis reported by
the International Pediatric
Peritonitis Registry (IPPR)
(with permission from [14]).
MRSA Methicillin-resistant
Staphylococcus aureus, coag.
Neg. Staph coagulase-negative
staphylococcus
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report of the NAPRTCS [2]. Yeasts belonging to the
Candida genus are the most common fungal organisms
implicated in peritonitis episodes. In the largest pediatric
report addressing this infection, Candida species accounted
for 79% of all fungal infections, with nearly 24% due to C.
albicans and more than 26% secondary to C. parapsilopsis
[37–39].
Mycobacterium tuberculosis is a very rare cause of
peritonitis and requires a peritoneal biopsy for a definitive
diagnosis [40]. Diphtheroid infections are most commonly
the result of skin organisms contaminating the peritoneum
by the intraluminal or periluminal route. Viruses have not
been confirmed to be the primary cause of any episodes of
peritonitis in pediatric CPD patients to date.
Pathogenesis
Peritonitis can result from bacteria reaching the peritoneum
by one of several routes: transluminal (mainly touch
contamination), periluminal (through an exit-site or tunnel
infection), enteric, hematogenous and, but only rarely,
ascending (through the vagina).
Coagulase-negative Staphylococcus characteristically
infects the peritoneum by the transluminal route following
touch contamination [28, 41]. The incubation period is
typically 24–48 h but may be as short as 6–12 h. This
organism is also commonly associated with recurrent
peritonitis due to biofilm formation. The decrease in the
overall incidence of peritonitis experienced during the past
decade is largely accounted for by a selective decrease in
the frequency of infection caused by this organism.
Staphylococcus aureus infections are commonly asso-
ciated with a catheter exit-site/tunnel infection with/without
S. aureus nasal carriage [28, 41]. In the IPPR data, 16% of
S. aureus peritonitis episodes were associated with S.
aureus nasal carriage [14]. S. aureus is also commonly
associated with recurrent peritonitis secondary to a catheter
tunnel infection. Symptoms of S. aureus peritonitis are
often more severe at presentation than those associated with
coagulase-negative Staphylococcus, as demonstrated by
disease severity score data collected by the IPPR, and
clinical improvement is typically slower [14].
Streptococcus and Enterococcus generally account
for fewer than 5% of peritonitis episodes each [28].
Streptococci usually belong to the alpha-hemolytic group
of bacteria and often cause peritonitis by hematogenous
spread, either following a dental procedure or possibly
originating from the respiratory tract, the skin, or the bowel.
Enterococcal peritonitis is often severe; the organisms are
fecal in origin, which often suggests a transmural route of
infection. The emergence of vancomycin-resistant organ-
isms in this species has been associated with an increased
risk for patient mortality [42, 43].
Gram-negative infections are caused by a wide variety of
organisms and are usually acquired by touch contamination,
intra-abdominal pathology (e.g. ischemic colitis, ruptured
appendicitis), or a catheter-related infection. The detection
of enteric bacteria is indicative of fecal contamination, and
intra-abdominal sources of infection should be suspected
when multiple Gram-negative organisms are cultured. In
this setting, anaerobic organisms should be looked for as
well. Pseudomonas/Stenotrophomonas species are the most
common Gram-negative species causing catheter exit-site
and/or tunnel infections that result in peritonitis which
can be extremely resistant to treatment [11, 15]. The
organism may also form a biofilm on the catheter, thereby
precluding successful antibiotic management without
catheter removal. Gram-negative peritonitis is particularly
troublesome as it commonly results in severe abdominal
pain, is associated with dramatic alterations in the peri-
Fig. 2 Distribution of causative
organisms according to regions
among 501 episodes of perito-
nitis reported by the IPPR (with
permission from [13])
428 Pediatr Nephrol (2010) 25:425–440toneal membrane transport capacity, and may result in
techniquefailure[15, 44–46]. Finally, infections secondary
to Acinetobacter may be an indication of contamination
from a water source [47].
Risk factors associated with peritonitis and preventive
measures
The cause of peritonitis in most cases is not obvious. Of the
491 episodes of non-fungal peritonitis recently analyzed by
the IPPR, there were no identifiable factors associated with
72% of these. In the remainder, the most common causes
were touch contamination (12% of all episodes), exit-site/
tunnel infection (7%), and catheter perforation/leakage
(2.1%). The presence of a nasogastric tube, gastrostomy,
and a ureterostomy was associated with 9.5, 7, and 5.5% of
the 491 episodes [14]. Apart from these identified factors,
several other risk factors can heighten the incidence of
peritonitis in children, and an understanding of these is
important if one hopes to optimize prevention and patient
outcome.
Patient age While it is well known that the rate of
peritonitis in children is inversely related to age [2], recent
IPPR data have confirmed for the first time a statistical
association between young age and Gram-negative perito-
nitis [14, 15]. The reasons for the increased incidence of
infection in infants is not known, but it may in part be
related to the proximity of the catheter exit-site to the diaper
region or to gastrostomy/vesicostomy/nephrostomy sites
[14, 48]. In some centers, this issue has been successfully
addressed by placing the PD catheter exit-site in a chest
wall location [49, 50].
Catheter design Studies in children and adults have
repeatedly demonstrated that the time to first peritonitis
episode is significantly shorter and the peritonitis rate is
significantly higher when a catheter with one cuff is used as
opposed to a two-cuffed catheter [4, 51, 52]. The role of the
superficial cuff in preventing infection is primarily one of
anchoring the catheter to prevent trauma at the exit site
[53]. The preferred catheter in children, from the standpoint
of peritonitis risk, appears to be the double-cuffed swan
neck catheter with its inherent downward directed exit-site.
In fact, the NAPRTCS has demonstrated that the time to the
first peritonitis episode is significantly longer with the latter
PD access than with all other combinations of catheter
characteristics [2]. Nevertheless, data to the contrary do
exist [54–56].
Connection methodology The spiking of dialysis bags is a
“high-risk” procedure because of the potential for contam-
ination of the system. The introduction of double-bag,
disconnect systems in CAPD, which eliminate the need for
spiking and permit the flushing of the connection site and
tubing with spent dialysate prior to the inflow of fresh
dialysate, has contributed to a marked reduction in the
incidence of peritonitis due to touch contamination. The
“flush before fill” procedure has also proven to be
beneficial in children and adults receiving APD [57, 58].
When spiking of bags is necessary, the Compact Assist
Device (Baxter Healthcare, Deerfield, IL) may decrease the
risk of contamination [59]. In the IPPR analysis, spiking
connection systems were associated with an increased risk
of acquiring Gram-negative peritonitis.
Prophylactic antibiotics A single dose of an intravenous
antibiotic given at the time of catheter placement decreases
the risk of a subsequent peritonitis episode [60–62]. While
a first-generation cephalosporin has been most frequently
used in this context, a single randomized trial did find that
vancomycin was superior to a cephalosporin in preventing
early peritonitis [60]. Prophylactic antibiotics are also
indicated following intraluminal contamination and prior
to dental procedures and procedures involving the gastro-
intestinal or urinary tract to decrease the risk of peritonitis
[11, 60, 63, 64].
Catheter-related infections and exit-site care Catheter exit-
site and tunnel infections, most often secondary to
Staphylococcus or Pseudomonas, are associated with a
significantly increased risk for the development of perito-
nitis [65–68]. It is important that, whenever possible,
dialysis initiation be delayed for 1–2 weeks after catheter
placement to allow for optimal surgical wound healing;
failure to do so predisposes to dialysate leakage with an
increased risk of infection. During the period of wound
healing, dressing changes should ideally not occur more
often than once per week and should be conducted by
trained dialysis personnel using an aseptic technique [69,
70]. In children receiving CPD, colonization of the catheter
exit-site with S. aureus and subsequent infection may not
only originate from S. aureus nasal carriage of the patient
[14, 71–74], but it may also come from family members
and caretakers since as many as 45% of families with
children on CPD have been found to have one or more
members with evidence of nasal carriage [75]. A number of
protocols for the prevention of S. aureus PD-related
infections have been examined [10], and it has been
reported that daily application of mupirocin cream to the
skin around the exit site is a cost-effective approach to
reducing S. aureus exit-site infection and peritonitis [76,
77]. However, emerging resistance to mupirocin and
preferential Pseudomonas colonization of exit-sites treated
with mupirocin has raised new concerns about this practice
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global variation in Gram-negative peritonitis may well be a
manifestation of exit-site care and mupirocin usage. The
incidence of Pseudomonas peritonitis was eightfold higher
in the USA than in Western Europe and was associated
with exit-site care practices characterized by daily washing
with non-sterile cleansing agents and the application of
mupirocin [13]. In the latest IPPR report on Gram-
negative peritonitis in children, 12% of the children with
Gram-negative peritonitis had the same microorganism
(most commonly Pseudomonas species) retrieved from the
peritoneal fluid and exit-site, but less than half of these
patients showed symptoms of a concurrent exit-site infec-
tion [15]. In turn, in a double-blinded randomized trial of
adult CPD patients, gentamicin cream applied daily to the
exit-site was found to be as effective as mupirocin in
reducing S. aureus exit-site infections as well as highly
effective in reducing Pseudomonas aeruginosa exit-site
infections [81]. Similar data have not yet been collected in
the pediatric population.
Training Training is an effective tool in reducing PD
infections. Patients receiving CPD in Japan routinely
experience very low peritonitis rates, probably as a result,
at least in part, of prolonged (6–7 weeks) training sessions
characterized by repetition and the understanding of PD
principles. Similar data emerged from an international
survey of 76 centers caring for children: the peritonitis rate
was lowest in those centers who devoted longer periods of
training to the topics of theory and practical/technical skills,
all provided by experienced PD nurses [82]. Training issues
may be particularly relevant to the >10% of patients who
develop peritonitis during the initial month of therapy [2].
Whereas the re-training of patients and caregivers should be
considered following any episode of peritonitis, it is espe-
cially pertinent for patients with recurrent peritonitis [82].
Antibiotic usage A majority of fungal peritonitis episodes
are preceded by a course(s) of antibiotics. A number of
studies have examined the use of antifungal prophylaxis
with either nystatin or fluconazole given during antibiotic
therapy to prevent fungal peritonitis, with mixed results.
Programs with high baseline rates of fungal peritonitis
found such an approach to be beneficial, while those with
low baseline rates did not detect a benefit [10, 38, 83–88].
Presence of gastrostomy While an earlier series of perito-
nitis episodes did not reveal any significant relationship
between the presence of a gastrostomy and the development
of fungal peritonitis in children [39], more recent IPPR data
did reveal a nearly (p=0.06) significant association between
Gram-negative peritonitis and the presence of a gastro-
stomy [14].
Presentation and diagnosis
Peritoneal dialysis patients presenting with abdominal pain
and/or cloudy effluent should be presumed to have
peritonitis and evaluated for this infection. While a small
percentage of pediatric and adult patients with peritonitis
may present with clear effluent and abdominal pain [10,
14], the presence of a cloudy peritoneal effluent almost
always indicates infectious peritonitis. However, there are a
number of non-infectious causes of cloudy peritoneal
effluent that should be recognized, including chemical
peritonitis, eosinophilic peritonitis, hemoperitoneum, chy-
lous ascites and, but only rarely, malignancy. As noted
previously, the severity of the presentation of abdominal
pain and fever in patients with peritonitis varies and is
somewhat organism-specific; for example, the severity is
generally mild–moderate with culture-negative peritonitis
and peritonitis secondary to coagulase-negative Staphylo-
coccus, whereas it is of greater severity with peritonitis
resulting from Streptococcus, Gram-negative organisms, S.
aureus, and fungi. An objective assessment of the severity
of a patient’s clinical status at presentation can be made by
evaluating the Disease Severity Score (DSS, 0–5), which is
defined by the sum of points for pain (0, no pain; 1,
moderate pain or nausea not requiring specific therapy; 2,
severe pain, usually requiring analgesic therapy,orvomiting;
3, peritoneal pain with a tense abdomen and/or paralytic
bowel) and fever (0, <37.5°C; 1, 37.5–38.9°C; 2, >38.9°C)
[89]. Data from the IPPR revealed that nearly half of the
121 Gram-negative peritonitis episodes occurred in children
aged <5 years and the initial clinical manifestations were
severe for the majority of patients [15].
The diagnosis of peritonitis is confirmed when the
effluent white blood cell (WBC) count is >100/mm
3 and
at least 50% of the WBCs are polymorphonuclear leuko-
cytes. However, the recent analysis by the IPPR did reveal
that the WBC count was <100 cells/μL in 2.8% of clinical
peritonitis episodes and that the percentage of polymor-
phonuclear cells was <50% in 8.5% of cases [14]. These
findings may be related to the fact that the number of cells
in the effluent is partly dependent on the length of the
exchange dwell. For patients on APD with short exchange
dwell times, a second exchange with a dwell time of
1–2 h should be carried out, reexamined for turbidity and
cell count, and sent for culture when peritonitis is suspected.
It is imperative that the diagnostic work-up of peritonitis
is performed according to a standardized protocol [10, 11]
as the correct culture techniques of peritoneal effluent are of
utmost importance for establishing the microorganism
responsible for the infection. The identification of both
the organism and subsequent antibiotic sensitivities not
only assists the clinician in selecting the most effective
antibiotic, but it can also help identify the possible source
430 Pediatr Nephrol (2010) 25:425–440of the infection. For details on the various culturing
techniques, the reader is referred to the ISPD guidelines
from 2000 and 2005 [10, 11]. When a standard culture
technique is used, culture-negative peritonitis should not
account for >20% of all peritonitis episodes, and centers
with higher rates should review and improve their culture
methodology [10].
Management of peritonitis
General guidelines
To prevent a delay in treatment, antibiotic therapy should
be initiated as soon as the diagnosis of peritonitis is
suspected and after samples of the dialysis effluent are
obtained for Gram stain, cell count and culture; if signs of
severe infection, such as pain and fever are present, it is
often advisable not to wait for confirmation of the cell
count from the laboratory. Several rapid flushes with
dialysis solution may be performed prior to the initiation
of antibiotic therapy to help reduce the severity of the
abdominal pain. In this case, because therapy is initiated
prior to knowledge of the causative organism, initial
empirically chosen antibiotics must cover both Gram-
positive and Gram-negative organisms.
Antibiotics selected for the treatment of peritonitis
should be administered intraperitoneally to ensure imme-
diate bioavailability, and recommendations for continuous
(provided in each exchange) and intermittent dosing are
available (Table 1)[ 11]. While evidence exists for the
efficacy of intermittent dosing of aminoglycosides, glyco-
peptides, and the third-generation cephalosporin ceftazidime,
most of this information is derived from adult patients on
CAPD [90–92]. In a randomized trial in children that
included both CAPD and APD patients, intermittent dosing
of a glycopeptide was as efficacious as continuous dosing in
patients with Gram-positive peritonitis, while intermittent
ceftazidime dosing in cases with Gram-negative peritonitis
was less successful than continuous treatment according to
clinical judgment, but not by the objective DSS criteria [89].
The recent IPPR analysis of 121 episodes of Gram-negative
peritonitis revealed a 14-fold increased risk of empiric
treatment failure associated with intermittent ceftazidime
therapy in comparison to continuous ceftazidime therapy and
also questions the advisability of the former approach [15].
When intermittent dosing is used, the antibiotic-containing
dialysis solution must be allowed to dwell for at least 6 h to
allow adequate absorption of the antibiotic into the systemic
circulation, which permits subsequent reentry into the
peritoneal cavity during ensuing fresh dialysis solution
exchanges. The rapid exchanges that often characterize
APD in children may be associated with an inadequate time
to achieve therapeutic intraperitoneal levels by the reentry
mechanism, and dwell times may need to be prolonged in
these situations. A recent pediatric study that evaluated the
disposition of intraperitoneal vancomycin in children has
suggested that an enhanced total body vancomycin elimina-
tion (relative to adults) coupled with a slow peritoneal
transfer, should prompt reevaluation of the current recom-
mendation for intermittent vancomycin therapy, particularly
in children receiving short-dwell PD regimens [93].
Even when continuous intraperitoneal antibiotic dosing
is used for children on APD, the dwell times should likely
be prolonged to 3–6 h for the initial 24–48 h of the therapy
until there is clearing of the peritoneal effluent. The
prolongation of the dwell time helps prevent depletion of
the cellular components of the local host defense mecha-
nism that may occur with frequent exchanges [94, 95].
However, prolongation of the dwell time may not be
necessary/advisable for asymptomatic patients or for those
with compromised ultrafiltration capacity and a need for
more frequent exchanges to maintain euvolemia.
It is recommended that the antibiotic containing dwell,
irrespective of whether the patient routinely receives CAPD
or APD, should be a full volume exchange (approximately
1100 mL/m
2 body surface area) during both day and
nighttime; in situations in which the exchange volume is
decreased during the initial 24–48 h of therapy because of
abdominal pain, the concentration of antibiotics must be
increased to ensure the infusion of the same mass of the
antibiotics that would be provided in a full dwell volume
[11]. The dose of any antibiotic that undergoes renal
excretion may also need to be increased in those patients
with residual kidney function [11].
Adjuvant therapy Patients with extremely cloudy effluent
may benefit from the addition of low-dose heparin (500–
1000 U/L) into the dialysate as it can help prevent
occlusion of the catheter due to fibrin, which is often
present as a result of the inflammatory process [96]. As
infants receiving CPD with peritonitis can lose substantial
amounts of gamma globulin across an inflamed peritoneum,
they may benefit from intravenous immunoglobulin (Ig)
therapy, especially if they have low measured IgG levels
and/or they appear septic [97, 98].
Antibiotic therapy
Initial (empiric) therapy The current pediatric peritonitis
treatment guidelines recommend the combination of either
a first-generation cephalosporin, such as cefazolin, or a
glycopeptide (vancomycin or teicoplanin) with a third-
generation cephalosporin, such as ceftazidime [11]. The
Pediatr Nephrol (2010) 25:425–440 431Table 1 Antibiotic dosing recommendations. Administration should be via intraperitoneal route unless specified otherwise
Antibiotics Continuous therapy Intermittent therapy
b
Loading dose
a Maintenance dose
Glycopeptides
Vancomycin 1000 mg/L 25 mg/L 30 mg/kg q 5–7 days
Teicoplanin
c 400 mg/L 20 mg/L 15 mg/kg q 5–7 days
Cephalosporins
Cefazolin/Cephalothin 500 mg/L 125 mg/L 15 mg/kg q 24 h
Cefuroxime 200 mg/L 125 mg/L 15 mg/kg q 24 h
Cefotaxime 500 mg/L 250 mg/L 30 mg/kg q 24 h
Ceftazidime 250 mg/L 125 mg/L 15 mg/kg q 24 h
Ceftizoxime 250 mg/L 125 mg/L –
Antifungals
Amphotericin B 1 mg/kg IV 1 mg/kg/day IV –
Fluconazole –– 3 – 6 mg/kg IP, IV or PO q
24–48 h (max. dose 200 mg)
Flucytosine 50 mg/kg IV or PO
(max. dose 2.0 g)
25–37.5 mg/kg PO/day
(max. dose 1.0 g)
−
Aminoglycosides
d
Amikacin 25 mg/L 12 mg/L –
Gentamicin 8 mg/L 4 mg/L –
Netilmicin 8 mg/L 4 mg/L –
Tobramycin 8 mg/L 4 mg/L –
Penicillins
d
Azlocillin 500 mg/L 250 mg/L –
Piperacillin – 250 mg/L 150 mg/kg IV q 12 h
Ampicillin – 125 mg/L –
Oxacillin – 125 mg/L –
Nafcillin – 125 mg/L –
Amoxicillin 250–500 mg/L 50 mg/L –
Quinolones
Ciprofloxacin 50 mg/L 25 mg/L –
Combinations
Ampicillin/Sulbactam 1000 mg/L 100 mg/L –
Imipenem/Cilastatin 500 mg/L 200 mg/L –
Trimethoprim/sulfamethoxazole 320/1600 mg/L 80/400 mg/L –
Others
Clindamycin 300 mg/L 150 mg/L –
Metronidazole –– 35–50 mg/kg/day PO in 3 doses
Rifampin –– 20 mg/kg/day PO (max. dose 600 mg/day)
Aztreonam 1000 mg/L 250 mg/L –
q, Every day; IV, Intravenously; IP,intraperitoneally; PO, orally
The therapeutic recommendations provided in this table are those of the ISPD Advisory Committee on Peritonitis Management in Pediatric
Patients and are, in large part, based upon adult experiences (used with permission from [11])
aLoading dose should be administered during a standardized 3- to 6-h dwell period. Concentration-related loading doses assume usual patient-
specific fill volume (i.e. approximately 1100 mL/m
2 body surface area). If a smaller volume is instilled, the concentration must be increased to
ensure infusion of an equal mass of antibiotic. Intermittent antibiotic dosing should be administered over ≥6 h in one bag per day for continuous
ambulatory peritoneal dialysis (CAPD) patients, or during a full fill volume daytime dwell for automated peritoneal dialysis (APD) patients,
unless otherwise specified
bAccelerated glycopeptide elimination may occur in patients with residual renal function. Intermittent therapy is used in this setting. The second
dose of antibiotic should be time-based on a blood level obtained 3–5 days after the initial dose. Redosing should occur when the blood level
is <12 mg/L for vancomycin or 8 mg/L for teicoplanin. Intermittent therapy is not recommended for patients with residual renal function
unless serum drug levels can be monitored in a timely manner
cTeicoplanin is not currently available in the USA
dAminoglycosides and penicillins should not be mixed in dialysis fluid because of the potential for inactivation
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nation in “high-risk patients” or those thought to be at high
risk for severe disease based on their young age, a history
of S. aureus infection, or a history of a recent catheter-
related infection was based on the increasing prevalence of
methicillin resistance and the expected severe clinical
course in these patients. The decision was also influenced
by the superiority of this combination in a meta-analysis of
studies performed in adults and it’s safety and efficacy
profile in children [29, 89, 99–101]. The recommendation
is, however, that glycopeptide usage be restricted to high-
risk patients because of the fear of promoting vancomycin-
resistant enterococci and the potential emergence of
glycopeptide-resistant staphylococci [42, 43, 102–104].
Finally, the choice of ceftazidime over aminoglycosides
was influenced by the potential for a high cumulative
exposure to the latter, with possible resultant ototoxicity
and nephrotoxicity [105]. The latter assumes significance in
view of the considerable residual kidney function that is
commonly present in children with hypoplastic kidney
disorders and that may have a positive impact on patient
outcome [106–108].
Once culture results and sensitivities are known,
antibiotic therapy should be adjusted appropriately. The
current pediatric peritonitis treatment guidelines for therapy
modification according to dialysate culture results are as
follows:
& Gram-positive peritonitis. The empiric use of ceftazidime
should be discontinued. For methicillin-sensitive staphy-
lococci, the first generation cephalosporin should be
continued or should replace the empiric glycopeptide.
For patients with methicillin-resistant staphylococci, a
glycopeptide (vancomycin or teicoplanin) should be
continued or should replace the first-generation cephalo-
sporin. Clindamycin is a satisfactory alternative for those
who do not tolerate glycopeptide antibiotics. Ampicillin
is a suitable monotherapy for peritonitis caused by
enterococci and streptococci and can be replaced with
clindamycin or a glycopeptide if organisms are resistant
to ampicillin. Treatment duration should be 2 weeks for
all organisms except S. aureus, for which therapy should
be 3 weeks [11].
& Gram-negative peritonitis.Uponculture ofa singleGram-
negative organism, the first-generation cephalosporin or
glycopeptide should be discontinued and ceftazidime
continued if the organism is sensitive to ceftazidime and
the patient is responding well clinically. However, if the
organismbelongstothePseudomonas/Stenotrophomonas
genus, a second antibiotic with synergistic activity (e.g.
an aminoglycoside) should be added. If multiple Gram-
negative organisms or anaerobic bacteria are grown,
metronidazole should be added and the patient should be
investigated for intra-abdominal pathology. The recom-
mended duration of treatment is 3 weeks for Pseudomo-
nas/Stenotrophomonas species, multiple organisms, and/
or anaerobic organisms, and 2 weeks for other single
Gram-negative organisms [11].
& Culture-negative peritonitis. In cases where the culture
remains sterile and the patient’s clinical condition is
improving, combined empiric therapy should be con-
tinued for 2 weeks [11]. However, prolonged therapy
with an aminoglycoside is discouraged because of the
concern for toxicity.
The recent analysis of 491 episodes of non-fungal
peritonitis by the IPPR has provided the opportunity to
evaluate the efficacy of the recommendations regarding
antibiotic therapy [14]. Of interest, the analysis did not
support the earlier opinion-based recommendation of
assigning young infants as well as children with a severe
clinical presentation, previous or ongoing exit-site infection,
or a methicillin-resistant S. aureus history preferentially to
glycopeptide treatment, as no significant correlation was
seen between the presence of the previously described risk
factors, the empiric antibiotic therapy chosen, and either the
early treatment response or the final functional outcome. The
reason for this inconsistency was primarily due to significant
in vitro resistance to ceftazidime in patients with Gram-
negative peritonitis. This group of patients responded
better clinically to a combination of a first-generation
and third-generation cephalosporin than to a combination
of ceftazidime and a glycopeptide, likely due to a mani-
festation of synergy between the former pair of anti-
biotics (vide infra). Overall, only 80% of Gram-negative
organisms showed in vitro sensitivity to ceftazidime,
whereas the proportion of sensitive organisms increased
to 91% for the combination of a first-generation and third-
generation cephalosporin and to 93% for the combination
of a first-generation cephalosporin and an aminoglycoside.
The sensitivity of Gram-negative organisms to aminoglyco-
sides varied globally, ranging from 82% in Eastern Europe
to 96% in Western Europe [13].
The sensitivity of Gram-positive organisms to glycopep-
tide antibiotics was consistently high (96–100%), but their
sensitivity to a first-generation cephalosporin varied by
country—from 50% in the USA to 94% in Eastern Europe.
Overall, only 69% of Gram-positive organisms were
sensitive to either cefazolin or cephalothin, and the com-
bined sensitivity increased to 94% when an aminoglycoside
was combined with the former antibiotic. In vitro evalua-
tion revealed that 50% of the coagulase negative staphylo-
cocci and 14% of the S. aureus strains were resistant to
methicillin. Finally, 90% of the Gram-positive organisms
tested and 96% of the Gram-negative organisms tested were
sensitive to ciprofloxacin [14].
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susceptibility is likely the result of antibiotic preferences in
different regions, which in turn are influenced by local
experience and treatment guidelines, cost considerations
and, at least for some drugs, availability issues and marketing
activities. These issues and the data collected by the IPPR
support the latest ISPD recommendations that the empiric
antibiotic therapy of peritonitis should take into account the
patient- and center-specific history of microorganisms and
their sensitivity pattern [10, 109]. Antibiotic resistance
patterns should be monitored on a regular basis, and the
treatment protocol should cover all serious pathogens that
are prevalent in that region. The limited success in treating
Gram-negative infections with ceftazidime, the substantial
morbidity associated with these infections, and the greater
susceptibility of Gram-negative organisms to aminoglyco-
sides emphasize the importance of considering possible
modification of current empiric antibiotic therapy recommen-
dations. While repeated or prolonged courses of aminoglyco-
side therapy are likely not advisable, their short-term use
appears to be safe and without detrimental effect on residual
kidneyfunction[110]. When the aminoglycoside antibiotic is
used as part of the empiric regimen, there should be prompt
modification of antibiotic management once susceptibility
data reveal that the causative organism is resistant to that
aminoglycoside antibiotic or that another, less toxic antibi-
otic displays evidence of equivalent in vitro efficacy. In the
case of culture-negative peritonitis, substitution of the
aminoglycoside with ceftazidime is likely to be preferable.
Although the IPPR data suggests that ciprofloxacin may
be an ideal single agent, providing broad spectrum
coverage against both Gram-positive and Gram-negative
organisms, the potential for rapid development of bacterial
resistance and the possible risk of interference with
cartilage development in young children make this a less
desirable choice for initial therapy [111, 112].
Assessment of initial response
The patient’s clinical condition should be assessed daily
subsequent to the initiation of therapy. An assessment of the
dialysis effluent after 3 days of therapy will typically reveal
the dialysate leukocyte count to have decreased by more
than 50%, with a shift from a predominance of poly-
morphonuclear to mononuclear cells. It is noteworthy that,
on occasion, microorganisms may still grow in the
peritoneal cavity after 72 h of treatment, particularly in
patients receiving intermittent antibiotic administration.
These positive cultures, however, do not predict a poor
outcome [89].
Failure to respond within 72 h of therapy initiation
should prompt further investigation, including a repeat
assessment of the dialysate cell count, Gram stain, and
culture, an assessment of the catheter tunnel and exit-site by
clinical and, possibly, ultrasound evaluation, and an exit-
site culture [113, 114].
Management of refractory peritonitis
The most common cause of treatment-resistant peritonitis
is a catheter tunnel-related infection, usually due to a S.
aureus or P. aeruginosa infection of the subcutaneous tissue
around the catheter cuffs [11, 115]. The confirmation of a
tunnel infection in therapy-resistant peritonitis necessitates
immediate removal of the catheter, followed by 2–3 weeks
of temporary hemodialysis and intravenous antibiotic
therapy before a new catheter can be inserted, preferably
on the contralateral side [11].
In patients whose peritoneal fluid culture is positive for
anaerobic bacteria or multiple Gram-negative organisms,
the possibility of intra-abdominal pathology (e.g. ruptured
appendix) should be considered. Another possible explana-
tion of antibiotic-resistant peritonitis is fungal infection,
which usually develops following antibiotic treatment of
bacterial peritonitis but can occur without any risk factors
in a substantial number of patients [37–39]. If fungi are
identified by Gram stain or culture, all antibiotics should
be discontinued and antimycotic treatment initiated with
either intravenous amphotericin B or a combination of an
imidazole/triazole (e.g. intravenous or oral fluconazole) and
flucytosine (if available). Whereas amphotericin B has
historically been recommended as the primary treatment for
fungal peritonitis in patients receiving PD, data collected in
children and adults provide evidence that the peritoneal
penetration of amphotericin B following systemic adminis-
tration is poor [116]. In contrast, fluconazole is character-
ized by excellent bioavailability and peritoneal penetration
and is almost always active against Candida species [117].
Unfortunately, fungi usually colonize the surface of the
silastic material of the catheter, thereby making medical
therapy rather futile. Accordingly, in virtually all circum-
stances, the prognosis for successful management of the
infection and for the potential of ongoing PD will be
improved by immediate catheter removal [10]. Antimycotic
treatment should be continued during temporary hemodial-
ysis for at least 2 weeks after the complete resolution of
clinical symptoms and before placement of a new PD
catheter is considered [11].
Relapsing peritonitis
Relapsing peritonitis is defined as the recurrence of
peritonitis with the same organism as in the immediately
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susceptibilities, within 4 weeks of completion of antibiotic
treatment. Relapsing peritonitis may occur in up to 20%
of initially antibiotic-responsive Gram-positive peritonitis
episodes. The most common microorganisms causing
relapsing peritonitis are slime-forming coagulase-negative
staphylococci that can survive antibiotic treatment in
fibrinous adhesions and in the biofilm matrix on the
catheter surface [118]. Staphylococcus aureus and P.
aeruginosa, which may cause subclinical microabscesses
in the tunnel region or in intra-abdominal adhesions, may
also be the source of this complication. Ultrasound
assessment can assist in the detection of clinically occult
tunnel infections [119].
Since the causative organism of relapsing peritonitis is
not known when clinical symptoms occur, empiric treatment
should be reinitiated initially. After confirmation of the
relapse by culture and antibiotic susceptibilities, organism-
specific treatment should be continued for 3 weeks. Early
catheter removal is recommended in cases where the origin
of the re-infection can be localized to the catheter tunnel and
in any case of a relapsing infection with Pseudomonas or
Stentrophomonas species.
Catheter removal and reinsertion
Peritoneal dialysis catheter removal should be seen as part
of the recommended peritonitis management in situations in
which failure to do so is unlikely to result in a successful
outcome. The primary goal in managing peritonitis should
always be the optimal treatment of the patient and
protection of the peritoneum—and not saving the catheter.
Whereas there are no data to permit an evidence-based
recommendation with respect to the length of antibiotic
treatment following catheter removal and the appropriate
time for catheter replacement, an interval of 2–3 weeks
between catheter removal and catheter replacement with at
least 2 weeks of systemic antibiotic therapy during the
intervening period is considered to be acceptable [11].
Simultaneous catheter removal and reinsertion can, on
occasion, obviate the need for interval hemodialysis and has
been successfully reported in cases with recurrent peritonitis,
relapsing peritonitis (unless caused by Pseudomonas/Stentro-
phomonas species), and refractory exit-site or tunnel infec-
tions, including those caused by Pseudomonas species [120–
123]. In patients with refractory exit-site infection, timely
replacement of the catheter can decrease the risk of peritonitis.
Catheter exchange associated with peritonitis should be
performed once the infection has responded to antibiotics and
the effluent cell count is <100 leukocytes/µl [124], and this
procedure should be followed by 3 weeks of appropriate
antibiotic therapy. Simultaneous catheter removal and rein-
sertion is not advocated for refractory and fungal peritonitis.
Final outcome
Peritonitis is the primary reason for technique failure in
children receiving CPD. According to the 2007 NAPRTCS
annual report, 675 patients entered in the dialysis registry
discontinued PD for reasons other than transplantation, with
excessive infection being the primary reason for discon-
tinuation in 42.8% of these cases [2].
Based on the IPPR experience, 89% of peritonitis episodes
were followed by full functional recovery (Fig. 3). Peritoneal
dialysis was permanently discontinued (technique failure) in
8.1% of cases because of persistent ultrafiltration problems,
abdominal adhesions, persistent infection, secondary devel-
opment of fungal peritonitis, or general therapy failure. The
outcome of infections caused by Pseudomonas species
tended to be the least favorable, with only 74% of the cases
achieving full recovery. When outcome was compared by
geographic region, the final outcome was significantly less
favorable in Eastern Europe, where PD was permanently
discontinued in 20% of patients. This poor outcome was
associated with the preferential usage of straight rather than
coiled Tenckhoff catheters, a practice that may predispose to
inferior drainage in patients with post-peritonitic adhesions
[13]. Relapsing peritonitis occurred in 52 cases, and full
Fig. 3 Peritonitis outcome by
organisms as reported by the
IPPR (with permission from
[14]). Coag. Neg. Staph coagu-
lase-negative Staphylococcus
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(75%) than in those who had episodes without relapse (91%)
[14].
The mortality rate in children who develop acute
peritonitis is approximately 1% [125]. Six deaths were
reported by the IPPR, representing 1.2% of the peritonitis
episodes. Three of these deaths were associated with the
development of Gram-negative peritonitis. Repeated episodes
of peritonitis have been associated with patient mortality
following the development of sclerosing encapsulating
peritonitis [126, 127].
Concluding paragraph
Peritonitis remains the most significant complication of PD
in children. New technologies and a better understanding of
the epidemiology of the infection should result in greater
success in terms of prevention and treatment, with resultant
preservation of PD as a viable long-term dialysis modality
for the pediatric patient.
Questions
(Answers are given following the questions)
1. The microbiology of peritoneal dialysis-associated
peritonitis is best characterized by which of the
following?
A. 50–60% Gram-positive organisms and 25% fungi
B. 50–60% Gram-positive organisms and 20–30%
Gram-negative organisms
C. 50–60% Gram-negative organisms, 5% Gram-
positive organisms, and 25% culture negative
D. 50–60% Gram-negative, 25% culture-negative,
and 15% viral
E. 50–60% Gram-positive organisms, 20% fungi, and
30% culture-negative
2. Which one of the routes listed below is not a common
route by which bacteria may reach the peritoneum and
cause peritoneal dialysis-associated peritonitis?
A. Hematogenous
B. Periluminal
C. Enteric
D. Transluminal
E. Transhepatic
3. Which of the following organisms are frequently
associated with catheter exit-site and tunnel infections
and may predispose to the development of peritonitis?
A. Escherichia coli
B. Klebsiella
C. Acinetobacter
D. Pseudomonas
E. Streptococcus
4. The dialysis effluent cell count characteristic of
peritoneal dialysis associated bacterial peritonitis is
which of the following?
A. Greater than 100/mm
3 WBC with at least 50%
polymorphonuclear leukocytes
B. Greater than 1000/mm
3 WBC with at least 15%
polymorphonuclear leukocytes
C. Greater than 50/mm
3 WBC with at least 15%
eosinophils
D. Greater than 100/mm
3 WBC with fewer than 50%
polymorphonuclear leukocytes
E. Less than 100/mm
3 WBC with more than 50%
lymphocytes
5. The IPPR has recently found that the in vitro sensitivity
of Gram-positive organisms to a first-generation ceph-
alosporin is which of the following?
A. 100%
B. 85%
C. 69%
D. 10%
E. 35%
References
1. Alexander SR, Warady BA (2004) The demographics of dialysis
in children. In: Warady BA, Schaefer FS, Fine RN, Alexander
SR (eds) Pediatric dialysis. Kluwer, Dordrecht, pp 35–46
2. North American Pediatric Renal Trials and Cooperative Studies
(NAPRTCS) (2007) 2007 Annual report. EMMES Corp,
Rockville
3. Szeto CC, Chow KM, Wong TY, Leung CB, Li PK (2003)
Influence of climate on the incidence of peritoneal dialysis-
related peritonitis. Perit Dial Int 23:580–586
4. Warady BA, Sullivan EK, Alexander SR (1996) Lessons from
the peritoneal dialysis patient database: a report of the North
American Pediatric Renal Transplantation Cooperative Study.
Kidney Int 53:S68–S71
5. Tranaeus A (1998) Peritonitis in pediatric continuous peritoneal
dialysis. In: Fine RN, Alexander S, Warady BA (eds) CAPD/
CCPD in children. Kluwer, Norwell, pp 301–347
6. U.S. Renal Data System (USRDS) (2007) 2007 Annual data
report: atlas of end-stage renal disease in the United States.
National Institute of Health, National Institute of Diabetes and
Digestive and Kidney Diseases, Bethesda
7. Keane WF, Everett ED, Golper TA, Gokal R, Halstenson C,
Kawaguchi Y, Riella M, Vas S, Verbrugh HA (1993) Peritoneal
dialysis-related peritonitis treatment recommendations: 1993
update. The Ad Hoc Advisory Committee on Peritonitis
Management. International Society for Peritoneal Dialysis. Perit
Dial Int 13:14–28
8. Keane WF, Alexander SR, Bailie GR, Boeschoten E, Gokal R,
Golper TA, Holmes CJ, Huang CC, Kawaguchi Y, Piraino B,
436 Pediatr Nephrol (2010) 25:425–440Riella M, Schaefer F, Vas S (1996) Peritoneal dialysis-related
peritonitis treatment recommendations: 1996 update. Perit Dial
Int 16:557–573
9. Keane WF, Bailie GR, Boeschoten E, Gokal R, Golper TA,
Holmes CJ, Kawaguchi Y, Piraino B, Riella M, Vas S (2000)
Adult peritoneal dialysis-related peritonitis treatment recommen-
dations: 2000 update. Perit Dial Int 20:828–829
10. Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A,
Holmes C, Kuijper EJ, Li PKT, Lye WC, Mujais S, Paterson DL,
Fontan MP, Ramos A, Schaefer F, Uttley L (2005) Peritoneal
dialysis-related infections recommendations: 2005 update. Perit
Dial Int 25:107–131
11. Warady BA, Schaefer F, Holloway M, Alexander S, Kandert M,
Piraino B, Salusky I, Tranaeus A, Divino J, Honda M, Mujais S,
Verrina E, for the International Society for Peritoneal Dialysis
(ISPD) (2000) Advisory Committee on Peritonitis Management
in Pediatric Patients: consensus guidelines for the treatment of
peritonitis in pediatric patients receiving peritoneal dialysis. Perit
Dial Int 20:610–624
12. Feneberg R, Warady BA, Alexander SR, Schaefer F, Members of
the International Pediatric Peritoneal Registry (2004) The
International Pediatric Peritoneal Registry: a global internet-
based initiative in pediatric dialysis. Perit Dial Int 24:S130–S134
13. Schaefer F, Feneberg R, Aksu N, Donmez O, Sadikoglu B,
Alexander SR, Mir S, Ha IS, Fischbach M, Simkova E, Watson
AR, Moller K, von Baum H, Warady BA (2007) Worldwide
variation of dialysis-associated peritonitis in children. Kidney Int
72:1374–1379
14. Warady BA, Feneberg R, Verrina E, Flynn JT, Muller-Wiefel
DE, Besbas N, Zurowska A, Aksu N, Fischbach M, Sojo E,
Donmez O, Sever L, Sirin A, Alexander SR, Schaefer F (2007)
Peritonitis in children who receive long-term dialysis: a
prospective evaluation of therapeutic guidelines. J Am Soc
Nephrol 18:2172–2179
15. Zurowska A, Feneberg R, Warady BA, Zimmering M,
Monteverde M, Testa S, Calyskan S, Drozdz D, Salusky I,
Kemper MJ, Ekim M, Verrina E, Misselwitz J, Schaefer F
(2008) Gram-negative peritonitis in children undergoing long-
term peritoneal dialysis. Am J Kidney Dis 51:455–462
16. Burkart J, Hylnader B, Durnell-Figel T, Roberts D (1990)
Comparison of peritonitis rates during long-term use of standard
spike versus Ultraset in continuous ambulatory peritoneal
dialysis (CAPD). Perit Dial Int 10:41–43
17. Burkart J, Jordan JR, Durnell TA, Case LD (1992) Comparison
of exit-site infections in disconnect versus nondisconnect
systems for peritoneal dialysis. Perit Dial Int 12:317–320
18. Valeri A, Radhakrishnan J, Vernocci L, Carmichael LD, Stern L
(1993) The epidemiology of peritonitis in acute peritoneal
dialysis: A comparison between open- and closed-drainage
systems. Am J Kidney Dis 21:300–309
19. Monteon F, Correa-Rotter R, Paniagua R, Amato D, Hurtado
ME, Medina JL, Salcedo RM, Garcia E, Matos M, Kaji J,
Vazquez R, Ramos A, Schettino MA, Moran J (1998) Prevention
of peritonitis with disconnect systems in CAPD: A randomized
controlled trial. Kidney Int 54:2123–2128
20. Li PK, Law MC, Chow KM, Chan WK, Szeto CC, Cheng YL,
Wong TY, Leung CB, Wang AY, Lui FS, Yu AW (2002)
Comparison of clinical outcome and ease of handling in two
double-bag systems in continuous ambulatory peritoneal dialy-
sis: a prospective, randomized controlled, multicenter study. Am
J Kidney Dis 40:373–380
21. Kim DK, Yoo TH, Ryu DR, Xu ZG, Kim HJ, Choi KH, Lee
HY, Han DS, Kang SW (2004) Changes in causative organisms
and their antimicrobial susceptibilities in CAPD peritonitis: a
single center’s experience over one decade. Perit Dial Int
24:424–432
22. Benfield MR, McDonald R, Sullivan EK, Stablein DM, Tejani A
(1999) The 1997 annual renal transplantation in children: Report
of the North American Pediatric Renal Transplant Cooperative
Study (NAPRTCS). Pediatr Transplant 2:152–167
23. Verrina E, Bassi S, Perfumo F, Edefonti A, Zacchello G,
Andreetta B, Pela I, Penza R, Piaggio G, Picca M (1993)
Analysis of complications in a chronic peritoneal dialysis
pediatric patient population. The Italian Registry of Pediatric
Patient Population. Perit Dial Int 13:S257–S259
24. Schaefer F, Klaus G, Muller-Wiefel DE, Mehls O (1999) Current
practice of peritoneal dialysis in children: Results of a longitu-
dinal survey. Perit Dial Int 2:S445–S449
25. Honda M, Iitaka K, Kawaguchi H, Hoshii S, Akashi S, Kohsaka
T, Tuzuki K, Yamaoka K, Yoshiwaka N, Karashima S, Itoh Y,
Hatae K (1996) The Japanese national registry data on pediatric
CAPD patients: a ten year experience. A report of the study
group of pediatric PD conference. Perit Dial Int 16:269–275
26. Schaefer F, Kandert M, Feneberg R (2002) Methodological
issues in assessing peritonitis incidence in children. Perit Dial Int
22:234–238
27. Ramalakshmi S, Bernardini J, Piraino B (2003) Nightly
intermittent peritoneal dialysis to initiate peritoneal dialysis.
Adv Perit Dial 19:111–114
28. Vas S, Oreopoulos DG (2001) Infections in patients undergoing
peritoneal dialysis. Infect Dis Clin North Am 15:743–774
29. Zelenitsky S, Barns L, Findlay I, Alfa M, Ariano R, Fine A,
Harding G (2000) Analysis of microbiological trends in
peritoneal dialysis-related peritonitis from 1991 to 1998. Am J
Kidney Dis 36:1009–1013
30. Piraino B, Bernardin J, Florio T, Fried L (2003) Staphylococcus
aureus prophylaxis and trends in Gram-negative infections in
peritoneal dialysis patients. Perit Dial Int 23:456–459
31. Mujais S (2006) Microbiology and outcomes of peritonitis in
North America. Kidney Int Suppl 103:S55–S62
32. MacGinley R, Cooney K, Alexander G, Cohen S, Goldsmith JA
(2002) Relapsing culture-negative peritonitis in peritoneal
dialysis patients exposed to icodextrin solution. Am J Kidney
Dis 40:1030–1035
33. Boer WH, Vos PF, Fieren MW (2003) Culture-negative
peritonitis associated with the use of icodextrin containing
dialysate in twelve patients treated with peritoneal dialysis. Perit
Dial Int 23:33–38
34. Toure F, Lavaud S, Mohajer M, Lavaud F, Canivet E, Nguyen P,
Chanard J, Rieu P (2004) Icodextrin-induced peritonitis: study of
five cases and comparison with bacterial peritonitis. Kidney Int
65:654–660
35. Martis L, Patel M, Giertych J, Mongoven J, Taminne M, Perrier
MA, Mendoza O, Goud N, Costigan A, Denjoy N, Verger C,
Owen WF Jr (2005) Aseptic peritonitis due to peptidoglycan
contamination of pharmacopoeia standard dialysis solution.
Lancet 365:588–594
36. Vychytil A, Remon C, Michel C, Wiliams P, Rodriguez-Carmona
A, Marron B, Vonesh E, van der Heyden S, Filho JC (on behalf of
the Extraneal Peritonitis Study Group) (2008) Icodextrin does not
impact infectious and culture-negative peritonitis rates in peritoneal
dialysis patients: a 2-year multicenter, comparative, prospective
cohort study. Nephrol Dial Transplant 23:3711–3719
37. Goldie SJ, Kiernan-Troidle L, Torres C, Gorban-Brennan N,
Dunne D, Kliger AS, Finkelstein FO (1996) Fungal peritonitis in
a large chronic peritoneal dialysis population: A report of 55
episodes. Am J Kidney Dis 28:86–91
38. Wang AYM, Yu AWY, Li PKT, Lam PKW, Leung CB, Lai
KN, Lui SF (2000) Factors predicating outcome of fungal
peritonitis in peritoneal dialysis: Analysis of a 9-year experi-
ence of fungal peritonitis in a single center. Am J Kidney Dis
36:1183–1192
Pediatr Nephrol (2010) 25:425–440 43739. Warady BA, Bashir M, Donaldson LA (2000) Fungal peritonitis
in children receiving peritoneal dialysis: a report of the
NAPRTCS. Kidney Int 58:384–389
40. Lui SL, Lo CY, Choy BY, Chan TM, Lo WK, Cheng IK (1996)
Optimaltreatmentandlong-termoutcomeoftuberculousperitonitis
complicating continuous ambulatory peritoneal dialysis. Am J
Kidney Dis 28:747–751
41. Piraino B (2000) Peritoneal infections. Adv Ren Replace Ther
7:280–288
42. Troidle L, Kilger AS, Gorban-Brennan N, Fikrig M, Golden M,
Finkelstein FO (1996) Nine episodes of CPD-associated peritonitis
with vancomycin-resistant enterococci. Kidney Int 50:1368–1372
43. Von Baum H, Schehl J, Geiss HK, Schaefer F (1999) Prevalence
of vancomycin-resistant enterococci among children with end-
stage renal failure. Clin Infect Dis 29:912–916
44. Holtta TM, Ronnholm KA, Holmberg C (1998) Influence of age,
time, and peritonitis on peritoneal transport kinetics in children.
Perit Dial Int 18:590–597
45. Andreoli SP, Leiser J, Warady BA, Schlichting L, Brewer ED,
Watkins SL (1999) Adverse effect of peritonitis on peritoneal
membrane function in children on dialysis. Pediatr Nephrol 13:1–6
46. Warady BA, Fivush B, Andreoli SP, Kohaut E, Salusky I,
Schlichting L, Pu K, Watkins S (1999) Longitudinal evaluation
of transport kinetics in children receiving peritoneal dialysis.
Pediatr Nephrol 13:571–576
47. Aflaiw A, Vas S, Oreopoulos DG (1999) Peritonitis in patients
on automated peritoneal dialysis. Contrib Nephrol 129:213–228
48. Schaefer F (2003) Management of peritonitis in children
receiving chronic peritoneal dialysis. Paediatr Drugs 5:315–325
49. Warchol S, Roszkowska-Blaim M, Sieniawska M (1998) Swan
neck presternal peritoneal dialysis catheter: Five-year experience
in children. Perit Dial Int 18:183–187
50. Chadha V, Jones LL, Ramirez ZD, Warady BA (2000) Chest
wall peritoneal dialysis catheter placement in infants with a
colostomy. Adv Perit Dial 16:318–320
51. Warady BA, Hebert D, Sullivan EK, Alexander SR, Tejani A
(1997) Renal transplantation, chronic dialysis, and chronic renal
insufficiency in children and adolescents. The 1995 annual report
of the North American pediatric renal transplant cooperative
study. Pediatr Nephrol 11:49–64
52. Furth SL, Donaldson LA, Sullivan EK, Watkins SL, North
American Pediatric Renal Transplant Cooperative Study (2000)
Peritoneal dialysis catheter infections and peritonitis in children:
A report of the North American Pediatric Renal Transplant
Cooperative Study. Pediatr Nephrol 15:179–182
53. Twardowski ZJ, Dobbie JW, Moore HL, Nichols WK, DeSpain
JD, Anderson PC, Khanna R, Nolph KD, Loy TS (1991)
Morphology of peritoneal dialysis catheter tunnel: macroscopy
and light microscopy. Perit Dial Int 11:237–251
54. Eklund B, Honkanen E, Kyllonen L, Salmela K, Kala AR (1997)
Peritoneal dialysis access: prospective randomized comparison
of single-cuff and double-cuff straight Tenckhoff catheters.
Nephrol Dial Transplant 12:2664–2666
55. Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC (2004)
Catheter type, placement and insertion techniques for preventing
peritonitis in peritoneal dialysis patients. Cochrane Database Syst
Rev (4):CD004680
56. Crabtree JH, Burchette RJ (2006) Prospective comparison of
downward and lateral peritoneal dialysis catheter tunnel-tract and
exit-site directions. Perit Dial Int 26:677–683
57. Smith CA (1997) Reduced incidence of peritonitis by utilizing
“flush before fill” in APD. Adv Perit Dial 13:224–226
58. Warady BA, Ellis EN, Fivush BA, Kum GM, Alexander SR,
Brewer ED, Ogrinc F, Watkins S (2003) Flush before fill in
children receiving automated peritoneal dialysis. Perit Dial Int
23:493–498
59. Verrina E, Honda M, Warady BA, Piraino B (2000) Prevention
of peritonitis in children on peritoneal dialysis. Perit Dial Int
20:625–630
60. Gadallah MF, Ramdeen G, Mignone J, Patel D, Mitchell L, Tatro
S (2000) Role of preoperative antibiotic prophylaxis in prevent-
ing postoperative peritonitis in newly placed peritoneal dialysis
catheters. Am J Kidney Dis 36:1014–1019
61. Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC (2004)
Antimicrobial agents for preventing peritonitis in peritoneal
dialysis patients. Cochrane Database Syst Rev (4):CD004679
62. Bonifati C, Pansini F, Torres DD, Navaneethan SD, Craig JC,
Strippoli GF (2006) Antimicrobial agents and catheter-related
interventions to prevent peritonitis in peritoneal dialysis: Using
evidence in the context of clinical practice. Int J Artif Organs
29:41–49
63. Sardegna KM, Beck AM, Strife CF (1998) Evaluation of
perioperative antibiotics at the time of dialysis catheter place-
ment. Pediatr Nephrol 12:149–152
64. Katyal A, Mahale A, Khanna R (2002) Antibiotic prophylaxis
before peritoneal dialysis catheter insertion. Adv Perit Dial
18:112–115
65. Piraino B (1996) Management of catheter-related infections. Am
J Kidney Dis 27:754–758
66. Piraino B (1997) Infectious complications of peritoneal dialysis.
Perit Dial Int 17:S15–S18
67. Piraino B (1998) Peritonitis as a complication of peritoneal
dialysis. J Am Soc Nephrol 9:1956–1964
68. Szeto CC, Chow KM, Leung CB, Wong TYH, Wu AKL, Wang
AYM, Lui SF, Li PKT (2001) Clinical course of peritonitis due
to Pseudomonas species complicating peritoneal dialysis: A
review of 104 cases. Kidney Int 59:2309–2315
69. Twardowski ZJ, Prowant BF (1997) Current approach to exit-site
infections in patients on peritoneal dialysis. Nephrol Dial
Transplant 12:1284–1295
70. Auron A, Simon S, Andrews W, Jones L, Johnson S, Musharaf
G, Warady BA (2007) Prevention of peritonitis in children
receiving peritoneal dialysis. Pediatr Nephrol 22:578–585
71. Luzar MA, Coles GA, Faller B, Slingeneyer A, Dah GD, Briat
C, Wone C, Knefati Y, Kessier M, Peluso F (1990) Staphylo-
coccus aureus nasal carriage and infection in patients on
continuous ambulatory peritoneal dialysis. N Engl J Med
322:505–559
72. Piraino B, Perlmutter JA, Holley JL, Bernardini J (1993)
Staphylococcus aureus peritonitis is associated with Staphylo-
coccus aureus nasal carriage in peritoneal dialysis patients. Perit
Dial Int 13:S332–S334
73. Blowey DL, Warady BA, McFarland KS (1994) The treatment of
Staphylococcus aureus nasal carriage in pediatric peritoneal
dialysis patients. Adv Perit Dial 10:297–299
74. Kingwatanakul P, Warady BA (1997) Staphylococcus aureus
nasal carriage in children receiving long-term peritoneal dialysis.
Adv Perit Dial 13:281–284
75. Oh J, von Baum H, Klaus G, Schaefer F, European Pediatric
Peritoneal Dialysis Study Group (EPPS) (2000) Nasal carriage of
Staphylococcus aureus in families if children on peritoneal
dialysis. Adv Perit Dial 16:324–327
76. Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R (1996) A
randomized trial of Staphylococcus aureus prophylaxis in perito-
neal dialysis patients: mupirocin calcium ointment 2% applied to
the exit-site versus cyclic oral rifampin. Am J Kidney Dis 27:695–
700
77. The Mupirocin Study Group (1998) Nasal mupirocin prevents
Staphylococcus aureus exit-site infection during peritoneal dialy-
sis. J Am Soc Nephrol 11:2403–2408
78. Miller MA, Dascal A, Portnoy J, Mendelson J (1996) Develop-
ment of mupirocin resistance among methicillin-resistant Staphy-
438 Pediatr Nephrol (2010) 25:425–440lococcus aureus after widespread use of nasal mupirocin ointment.
Concise Commun 17:811
79. Thomas DG, Wilson JM, Day MJ, Russell AD (1999) Mupirocin
resistance in staphylococci: Development and transfer of iso-
leucyl-tRNA systhetase-mediated resistance in vitro. J Appl
Microbiol 86:715–722
80. Annigeri R, Conly J, Vas S, Dedier H, Praskashan KP, Bargman
JM, Jassal V, Oreopoulos D (2001) Emergence of mupirocin-
resistant Staphylococcus aureus in chronic peritoneal dialysis
patients using mupirocin prophylaxis to prevent exit-sire infec-
tion. Perit Dial Int 21:554–559
81. Bernardini J, Bender F, Florio T, Sloand J, Palmmontalbano L,
Fried L, Piraino B (2005) Randomized, double-blind trial of
antibiotic exit site cream for prevention of exit site infection in
peritoneal dialysis patients. J Am Soc Nephrol 16:539–545
82. Holloway M, Mujais S, Kandert M, Warady BA (2001) Pediatric
peritoneal dialysis training: characteristics and impact on
peritonitis rates. Perit Dial Int 21:401–404
83. Zaruba K,Peters J, Jungbluth H(1991) Successful prophylaxis for
fungal peritonitis in patients on continuous ambulatory peritoneal
dialysis: six years’ experience. Am J Kidney Dis 17:43–46
84. Robitaille P, Merouani A, Clermont MJ, Hebert E (1995)
Successful antifungal prophylaxis in chronic peritoneal dialysis:
a pediatric experience. Perit Dial Int 15:77–79
85. Lo WK, Chan CY, Cheng SW, Poon JF, Chan DT, Cheng IK
(1996) A prospective randomized control study of oral nystatin
prophylaxis for candida peritonitis complicating continuous
ambulatory peritoneal dialysis. Am J Kidney Dis 28:549–552
86. Thodis E, Vas SI, Bargman JM, Singhal M, Chu M, Oreopoulos
DG (1998) Nystatin prophylaxis: its inability to prevent fungal
peritonitis in patients on continuous ambulatory peritoneal
dialysis. Perit Dial Int 18:583–589
87. Williams PF, Moncrieff N, Marriott J (2000) No benefit in using
nystatin prophylaxis against fungal peritonitis in peritoneal
dialysis patients. Perit Dial Int 20:352–353
88. Prasad KN, Prasad N, Gupta A, Sharma RK, Verma AK,
Ayyagari A (2004) Fungal peritonitis in patients on continuous
ambulatory peritoneal dialysis: a single centre Indian experience.
J Infect 48:96–101
89. Schaefer F, Klaus G, Mueller-Wiefel DE, Mehls O, Mid-
European Pediatric Peritoneal Dialysis Study Group (MEPPS)
(1999) Intermittent versus continuous intraperitoneal glycopeptide/
ceftazidimetreatmentinchildrenwithperitonealdialysis-associated
peritonitis. J Am Soc Nephrol 10:136–145
90. Boyce NW, Wood C, Thomson NM, Kerr P, Atkins RC (1988)
Intraperitoneal (IP) vancomycin therapy for CAPD peritonitis a
prospective, randomized comparison of intermittent v continuous
therapy. Am J Kidney Dis 12:304–306
91. Low CL, Bailie GR, Evans A, Eisle G, Venezia RA (1996)
Pharmacokinetics of once-daily IP gentamicin in CAPD patients.
Perit Dial Int 16:379–384
92. Low CL, Gopalakrishna K, Lye WC (2000) Pharmacokinetics of
once daily intraperitoneal cefazolin in continuous ambulatory
peritoneal dialysis patients. J Am Soc Nephrol 11:1117–1121
93. Blowey DL, Warady BA, Abdel-Rahman S, Frye RF, Manley HJ
(2007) Vancomycin disposition following intraperitoneal admin-
istration in children receiving peritoneal dialysis. Perit Dial Int
27:79–85
94. Jorres A, Topley N, Witowski J (1993) Impact of peritoneal
dialysis solutions on peritoneal immune defense. Perit Dial Int
13:S291–S294
95. Cameron JS (1995) Host defences in continuous ambulatory
peritoneal dialysis and the genesis of peritonitis. Pediatr Nephrol
9:647–662
96. de Boer AW, Levi M, Reddingius RE, Willems JL, van den Bosch
S, Schroder CH, Monnens LA (1999) Intraperitoneal hypercoagu-
lation and hypofibrinolysis is present in childhood peritonitis.
Pediatr Nephrol 13:284–287
97. Bouts AHM, Davin J-C, Krediet RT, van der Weel MB, Schroder
CH, Monnens L, Nauta J, Out TA (2000) Immunoglobulins in
chronic renal failure of childhood: effects of dialysis modalities.
Kidney Int 58:629–637
98. Neu AM, Furth SL, Lederman HM, Warady BA, Fivush B
(1998) Hypogammaglobulinemia in infants on peritoneal dialy-
sis. Perit Dial Int 18:440–443
99. Flanigan MJ, Lim VS (1991) Initial treatment of dialysis
associated peritonitis: A controlled trial of vancomycin versus
cefazolin. Perit Dial Int 11:31–37
100. Milliken SP, Matzke GR, Keane WF (1991) Antimicrobial
treatment of peritonitis associated with continuous ambulatory
peritoneal dialysis. Perit Dial Int 11:252–260
101. Mueller-Wiefel DE (1999) Treatment of peritonitis in pediatric
continuous peritoneal dialysis. Perit Dial Int 19:S450–S457
102. Hospital Infection Control Practices Advisory Committee
(HICPAC) (1995) Recommendations for preventing the spread
of vancomycin resistance. Infect Control Hosp Epidemiol
16:105–113
103. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV,
Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E,
Jarvis WR (1999) Emergence of vancomycin resistance in
Staphylococcus aureus. N Engl J Med 316:927–931
104. Sieradzki K, Roberts RB, Haber SW, Tomasz A (1999) The
development of vancomycin resistance in a patient with
methicillin-resistant Staphylococcus aureus infection. N Engl J
Med 340:517–523
105. Warady BA, Reed L, Murphy G, Kastetter S, Karlsen E, Alon U,
Hellerstein S (1993) Aminoglycoside ototoxicity in pediatric
patients receiving long-term peritoneal dialysis. Pediatr Nephrol
7:178–181
106. Shemin D, Maaz D, St Pierre D, Kahn SI, Chazan JA (1999)
Effect of aminoglycoside use on residual renal function in
peritoneal dialysis patients. Am J Kidney Dis 31:14–20
107. Singhal MK, Bhaskaran S, Vidgen E, Bargman JM, Vas SI,
Oreopoulos DG (2000) Rate of decline of residual renal function
in patients on continuous peritoneal dialysis and factors affecting
it. Perit Dial Int 20:429–438
108. Chadha V, Blowey DL, Warady BA (2001) Is Growth a valid
outcome measure of dialysis in children on peritoneal dialysis?
Perit Dial Int 21:S179–S184
109. Boeschoten EW, Ter Wee PM, Divinho J (2006) Peritoneal
dialysis-related infections recommendations 2005—an important
tool for quality improvement. Nephrol Dial Transplant 21:Sii31–
Sii33
110. Baker RJ, Senior H, Clemenger M, Brown EA (2003) Empirical
aminoglycosides for peritonitis do not affect residual renal
function. Am J Kidney Dis 41:670–675
111. Grady R (2003) Safety profile of quinolone antibiotics in the
pediatric population. Pediatr Infect Dis J 22:1128–1132
112. Noel GJ, Bradley JS, Kauffman RE, Duffy CM, Gerbino PG,
Arguedas A, Bagchi P, Balis DA, Blumer JL (2007) Comparative
safety profile of levofloxacin in 2523 children with a focus on
four specific musculoskeletal disorders. Pediatr Infect Dis
26:879–891
113. Gokal R,AlexanderSR, Ash S,ChenTW, Danielson A,Holmes C,
Joffe P, Moncrief J, Nichols K, Piraino B, Prowant B, Slingeneyer
A, Stegmayr B, Twardowski Z, Vas S (1998) Peritoneal catheters
and exit site practices. Toward optimum peritoneal access: 1998
update. Pediatr Dial Int 18:11–13
114. Vychytil A, Lorenz M, Schneider B, Horl WH, Haag-Weber M
(1998) New criteria for management of catheter infections in
peritoneal dialysis patients using ultrasonography. J Am Soc
Nephrol 9:290–296
Pediatr Nephrol (2010) 25:425–440 439115. Fried L, Piraino B (2000) Peritonitis. In: Gokal R, Khanna R,
Krediet R, Nolph K (eds) Textbook of peritoneal dialysis.
Kluwer, Norwell, pp 545–564
116. Blowey DL, Garg UC, Kearns GL, Warady BA (1998) Peritoneal
penetration of amphotericin B lipid complex and fluconazole in a
pediatric patient with fungal peritonitis. Adv Perit Dial 14:247–250
117. Dahl NV, Foote EF, Searson KM, Fein JL, Kapoian T, Steward
CA, Sherman RA (2000) Pharmacokinetics of intraperitoneal
fluconazole during continuous cycling peritoneal dialysis. Ann
Pharmacother 32:1284–1289
118. Klaus G, Schaer F, Querfeld U, Soergel M, Wolf S, Mehls O
(1992) Treatment of relapsing peritonitis in pediatric patients on
peritoneal dialysis. Adv Perit Dial 8:302–305
119. Plum J, Sudkamp S, Grabensee B (1994) Results of ultrasound-
associated diagnosis of tunnel infections in continuous ambula-
tory peritoneal dialysis. Am J Kidney Dis 23:99–104
120. Majkowski NL, Mendley SR (1997) Simultaneous removal and
replacement of infected peritoneal dialysis catheters. Am J
Kidney Dis 29:706–711
121. Posthuma N, Borgstein PJ, Eijsbouts Q, ter Wee PM (1998)
Simultaneous peritoneal dialysis catheter insertion and removal
in catheter-related infections without interruption of peritoneal
dialysis. Nephrol Dial Transplant 13:700–703
122. Lui SL, Li FK, Lo CY, Lo WK (2000) Simultaneous removal
and reinsertion of Tenckhoff cathetersfor treatment of refractory
exit-site infection. Adv Perit Dial 16:195–197
123. Lui SL, Yip T, Tse KC, Lam MF, Lai KN, Lo WK (2005)
Treatment of refractory Pseudomonas aeruginosa exit-site
infection by simultaneous removal and reinsertion of peritoneal
dialysis catheter. Perit Dial Int 25:560–563
124. Swartz RD, Messana JM (1999) Simultaneous catheter
removal and replacement in peritoneal dialysis infections:
update and current recommendations. Adv Perit Dial 15:205–
208
125. Warady BA, Schaefer FS (2004) Peritonitis. In: Warady BA,
Schaefer FS, Fine RN, Alexander SR (eds) Pediatric dialysis.
Kluwer, Dordrecht, pp 393–414
126. Honda M, Warady B (2008) Long-term peritoneal dialysis and
encapsulating peritoneal sclerosis in children. Pediatr Nephrol
doi:10.1007/s00467-008-0982-z
127. Maruyama Y, Nakayama M (2008) Encapsulating peritoneal
sclerosis in Japan. Perit Dial Int 28:S201–S204
Answers:
1. Correct answer: B
2. Correct answer: E
3. Correct answer: D
4. Correct answer: A
5. Correct answer: C
440 Pediatr Nephrol (2010) 25:425–440